Bristol Myers Squibb Deploys Nvidia DGX SuperPOD to Build Life Sciences AI Infrastructure

Bristol Myers Squibb announced the deployment of an Nvidia DGX SuperPOD equipped with DGX Vera Rubin NVL72 systems on July 20, 2026, marking a significant expansion of its nearly three-year collaboration with Nvidia. The company claims this infrastructure is the most powerful and energy-efficient single-owned Nvidia system in the life sciences industry. The Vera Rubin architecture delivers up to ten times greater performance per megawatt compared to its predecessor, allowing BMS to execute more computationally intensive AI workloads for drug discovery without proportional increases in energy consumption.

BMS has already integrated AI into its core research workflows in two major ways. First, AI agents automate target identification and validation, saving scientists weeks of manual effort and redirecting human effort toward hypothesis testing and high-value scientific decisions. Second, the company's "Predict First" methodology uses AI-generated predictions to inform experimental design before laboratory work begins; this approach now shapes the design of every small molecule program and the majority of its large molecule programs. Robert Plenge, executive vice president and chief research officer at BMS, stated: "This infrastructure lets us learn from every experiment and every clinical readout to sharpen the next hypothesis, allowing BMS scientists to spend less time on manual work and more time on the questions that require human judgment."

The expanded infrastructure underpins BMS's "hybrid intelligence" model, a framework in which AI co-scientists and human researchers work in close coordination. Under this model, AI systems handle the execution of complex, data-intensive tasks while scientists focus on direction, interpretation and decisions that require deep domain expertise. The Vera Rubin cluster will serve as the computational backbone for this approach and will support the development of next-generation foundation models trained on BMS's proprietary data accumulated over decades. The infrastructure will also leverage BioNeMo, Nvidia's platform for biological AI, and power agentic workflows that allow researchers to evaluate hypotheses at a scale previously not achievable. The cluster is expected to support BMS's scientific programs across oncology, hematology, cardiovascular disease, immunology and neuroscience. Greg Meyers, chief digital and technology officer at BMS, noted that "Expanding our compute capabilities with Nvidia gives our researchers and teams across the business the scale they need to keep BMS at the leading edge of what AI can do for drug discovery and development."

Bristol Myers Squibb's expansion of its Nvidia infrastructure reflects a deliberate, multi-year bet on AI as a core engine of drug discovery. The company has moved beyond pilot projects to embed AI into its workflow at scale—automating routine tasks like target identification while reserving human expertise for hypothesis generation and strategic decision-making. The Vera Rubin architecture's tenfold efficiency gain per megawatt is significant because it allows BMS to scale computational workloads without the operational overhead that typically accompanies infrastructure expansion in life sciences, where energy and cooling costs are substantial.

The deployment is positioned as the foundation for BMS's "hybrid intelligence" operating model, in which AI systems and human researchers collaborate rather than compete. By training proprietary foundation models on decades of internal scientific data and leveraging Nvidia's BioNeMo platform, BMS aims to convert its historical research investment into a competitive moat—proprietary models trained on data and domain context that competitors cannot easily replicate. The infrastructure spans the entire drug development pipeline, from target identification through clinical validation, suggesting BMS sees AI not as a point solution but as a systemic transformation of how it makes scientific decisions under uncertainty.

No comments yet. Be the first to share your thoughts!